IA
SNDX icon

Inspire Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Inspire Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-20,561
Closed -$299K – 370
2023
Q3 		$299K Sell
20,561
-20,721
-50% -$392K 0.05% 209
2023
Q2 		$864K Buy
41,282
+5,682
+16% +$118K 0.17% 56
2023
Q1 		$752K Buy
+35,600
New +$886K 0.17% 51

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Inspire Advisors's SNDX Position: Q4 2023 in Review

Inspire Advisors sold out of Syndax Pharmaceuticals (SNDX) in Q4 2023, closing a stake of 20,561 shares — an estimated $299K sold.

Inspire Advisors first reported a position in SNDX in Q1 2023 and held it in 3 quarters. The position peaked at $864K in Q2 2023. 177 funds tracked by Wall St. Rank hold SNDX as of Q4 2023.

  • Inspire Advisors reported no remaining Syndax Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Inspire Advisors sold 20,561 Syndax Pharmaceuticals shares in Q4 2023, an estimated $299K.
  • Inspire Advisors first reported a position in Syndax Pharmaceuticals in Q1 2023 and held it in 3 quarters.
  • Inspire Advisors's Syndax Pharmaceuticals position peaked at $864K in Q2 2023.
  • 177 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2023.

Based on Inspire Advisors's 13F filing for Q4 2023, filed 12 Feb 2024.